home / stock / eftr / eftr quote
Last: | $1.9799 |
---|---|
Change Percent: | 2.06% |
Open: | $1.93 |
Close: | $1.94 |
High: | $1.99 |
Low: | $1.93 |
Volume: | 7,478 |
Last Trade Date Time: | 05/20/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.9799 | $1.93 | $1.94 | $1.99 | $1.93 | 7,478 | 05-20-2024 |
$1.94 | $1.98 | $1.94 | $2 | $1.92 | 60,882 | 05-17-2024 |
$1.98 | $2.02 | $1.98 | $2.02 | $1.96 | 56,928 | 05-16-2024 |
$1.98 | $1.98 | $1.98 | $2.05 | $1.9411 | 111,232 | 05-15-2024 |
$2 | $2.01 | $2 | $2.0599 | $1.95 | 133,368 | 05-14-2024 |
$2 | $2.06 | $2 | $2.06 | $1.98 | 108,205 | 05-13-2024 |
$2.03 | $2.09 | $2.03 | $2.13 | $2 | 85,411 | 05-10-2024 |
$2.14 | $2.08 | $2.14 | $2.14 | $1.98 | 120,545 | 05-09-2024 |
$2.08 | $2.09 | $2.08 | $2.125 | $1.96 | 118,184 | 05-08-2024 |
$2.05 | $2.12 | $2.05 | $2.23 | $2.03 | 85,724 | 05-07-2024 |
$2.13 | $2.19 | $2.13 | $2.26 | $2.1 | 79,789 | 05-06-2024 |
$2.2 | $2.12 | $2.2 | $2.29 | $2.12 | 144,765 | 05-03-2024 |
$2.16 | $2.26 | $2.16 | $2.26 | $2.08 | 108,688 | 05-02-2024 |
$2.2 | $2.25 | $2.2 | $2.34 | $2.1691 | 60,661 | 05-01-2024 |
$2.25 | $2.07 | $2.25 | $2.27 | $2.0201 | 188,873 | 04-30-2024 |
$2.07 | $1.94 | $2.07 | $2.1255 | $1.9201 | 227,837 | 04-29-2024 |
$1.89 | $1.81 | $1.89 | $1.96 | $1.81 | 162,186 | 04-26-2024 |
$1.81 | $1.86 | $1.81 | $1.87 | $1.75 | 180,978 | 04-25-2024 |
$1.85 | $1.9 | $1.85 | $1.94 | $1.8 | 107,434 | 04-24-2024 |
$1.94 | $1.8 | $1.94 | $2 | $1.78 | 149,513 | 04-23-2024 |
News, Short Squeeze, Breakout and More Instantly...
eFFECTOR Therapeutics Inc. Company Name:
EFTR Stock Symbol:
NASDAQ Market:
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced a collaboration to conduct an investigator-spo...
Dose escalation of zotatifin in the ZFA triplet ongoing at 0.14 mg/kg, with RP2D expected in H2 2024 Raised $15.0 million in gross proceeds from registered direct financing, extending cash runway into first quarter of 2025 SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 09, 202...
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the Company will presen...